

## PRESS RELEASE

---

### ModeX COVID-19 Antibody Enters Phase I Developed on ProBioGen's Transposase Technology

**Berlin, Germany – June 30, 2026**

ProBioGen congratulates its partner ModeX Therapeutics Inc., an OPKO Health company, on the successful advancement of its antibody candidate MDX2301 into Phase I clinical development.

MDX2301 is a tetravalent antibody designed for the prevention of COVID-19 and aims to provide broad protection against diverse SARS-CoV-2 variants, particularly for individuals at increased risk of severe disease.

ProBioGen supported this milestone by developing the production cell line for MDX2301, applying its proven producer cell line [CHO.RiGHT®](#) to enable efficient manufacturing of this complex antibody format. The collaboration included advanced cell line development utilizing ProBioGen's pioneering [DirectedLuck®](#) Transposase Technology, which enabled the generation of high-titer, stable expression cell lines critical to the success of ModeX's antibody program.

This program is being funded in whole with federal funds from the U.S. Department of Health and Human Services (HHS) Administration for Strategic Preparedness and Response (ASPR), Biomedical Advanced Research and Development Authority (BARDA), under contract number 75A50123C00056. The contract and federal funding are not an endorsement of the project, product or company.

"We warmly congratulate ModeX on reaching this important milestone," said Dr. Volker Sandig, Chief Scientific Officer at ProBioGen. "It is rewarding to see complex, multispecific antibodies progressing to the clinic. We value the strong collaboration that enables this achievement and are proud that our DirectedLuck technology has contributed to it."

ProBioGen wishes the ModeX team continued success as the program advances.

#### About DirectedLuck

[DirectedLuck](#) is ProBioGen's next-generation transposase system, combining a highly active transposase/transposon pair with epigenetic targeting to insert multiple transgene copies into genomic regions with high transcriptional activity. This enables exceptionally high and stable protein expression in pools and clones, reducing timelines and manual clone selection efforts. The system is compatible with standard vector designs and diverse host cell lines. DirectedLuck delivers superior cell lines for mAbs, complex glycoproteins, and multi-specific antibody formats. The system is available for out-licensing and is routinely used in ProBioGen's client projects at no additional charge.

#### About ModeX

[ModeX Therapeutics](#) is a clinical-stage biopharmaceutical company developing innovative multispecific biologics for cancer and infectious disease. Its platforms unite the power of multiple biologics in a single molecule to create multispecific antibodies and vaccines with unprecedented versatility and potency in fighting complex disease. The ModeX pipeline includes candidates against both solid and hematologic tumors, as well as several of the world's most pressing viral threats. Its founding team includes globally recognized medical innovators with proven track records of delivering breakthroughs for patients. ModeX is an OPKO Health company based in Weston, Massachusetts.

#### About OPKO Health, Inc.

[OPKO](#) is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies.

## About ProBioGen

[ProBioGen](#) is a Berlin-based expert in the development and manufacturing of biopharmaceuticals, viral vectors, and vaccines, powered by proprietary technologies that enhance product quality and features. Its [CHO.RiGHT](#) platform enables fast, integrated cell line and process development, comprehensive analytics, and reliable GMP-compliant manufacturing, all supported by a highly experienced team. Operating for over 30 years, ProBioGen runs three manufacturing lines in Berlin, where 300 employees contribute to advancing next-generation therapies and global biotech innovation. The company's growth strategy focuses on expanding its service value chain through organic growth and strategic opportunities, with a clear mission to enable tomorrow's biopharmaceuticals.

For more information about ProBioGen, follow us on [LinkedIn](#).

### **ProBioGen Contact:**

Dr. Gabriele Schneider  
Chief Business Officer  
[cdmo@probiogen.de](mailto:cdmo@probiogen.de)

### **ProBioGen Press Contact:**

Sarah Wandrey  
Senior Communications Manager  
[press@probiogen.de](mailto:press@probiogen.de)